Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesity

Tests eloralintide against placebo in adults with painful knee osteoarthritis and excess weight.

Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Key facts

Where
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Ningbo, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan, and Xianyang, ChinaSee the 23 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with knee osteoarthritis pain who also have overweight or obesity (BMI of 27 kg/m² or higher) and have not lost weight through diet.

Age
18 years or older
Sex
All sexes can join
Disease stage
Osteoarthritis of the knee with pain, and at least one of: over 50 years old, morning knee stiffness lasting about 30 minutes, or a crackling or grinding feeling in the knee.
Earlier treatment
Must have tried at least once to lose weight through diet without success. Must not have taken weight-loss medications or alternative remedies within 90 days of screening.
Biomarker or test result
BMI of 27 kg/m² or higher at screening; stable body weight (less than 5% change) for 90 days before screening.

Main reasons for not taking part

  • Any type of diabetes (type 1, type 2 or other)
  • Surgery or endoscopic or device-based treatment for obesity (some exceptions if long ago)
  • Active knee infection
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
  • Class IV congestive heart failure (New York Heart Association)

Read by machine on 12 November 2026.

Where in China

  • Beijing Ji Shui Tan HospitalBeijing, ChinaContact: Xiaoli Deng (principal investigator)Taking people
  • The First Afflilated Hospital of Bengbu Medical CollegeBengbu, ChinaContact: Xiaoyun Fan (principal investigator)Taking people
  • Jilin Province People's HospitalChangchun, ChinaContact: Guoping Jiang (principal investigator)Taking people
  • The Second Hospital of Jilin UniversityChangchun, ChinaContact: Hanqing Cai (principal investigator)Taking people
  • Xiangya Hospital Central South UniversityChangsha, ChinaContact: Wenfeng Xiao (principal investigator)Taking people
  • 2nd Affiliated Hospital Chongqing Medical UniversiChongqing, ChinaContact: Mao Nie (principal investigator)Taking people
  • The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaContact: Haobo Wu (principal investigator)Taking people
  • The Second People's Hospital of HefeiHefei, ChinaContact: Jun Ye (principal investigator)Taking people
  • Jinan Central HospitalJinan, ChinaContact: Nianrong Mi (principal investigator)Taking people
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang, ChinaContact: Xiaofei Shi (principal investigator)Taking people
  • Jiangsu Province HospitalNanjing, ChinaContact: Hongwen Zhou (principal investigator)Taking people
  • Nanjing First HospitalNanjing, ChinaContact: Qian Li (principal investigator)Taking people
  • The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Yibing Lu (principal investigator)Taking people
  • Zhongda Hospital Southeast UniversityNanjing, ChinaContact: Jun Lu (principal investigator)Taking people
  • The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaContact: Xiudi Wu (principal investigator)Taking people
  • Huashan Hospital, Fudan UniversityShanghai, ChinaContact: Yu Xue (principal investigator)Taking people
  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Jie Zhao (principal investigator)Taking people
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaContact: Yunchao Shao (principal investigator)Taking people
  • The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Zhichun Liu (principal investigator)Taking people
  • Tianjin HospitalTianjin, ChinaContact: Jun Liu (principal investigator)Taking people
  • The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Chaoming Wu (principal investigator)Taking people
  • Tongji Hospital Tongji Medical,Science & TechnologyWuhan, ChinaContact: Lingli Dong (principal investigator)Taking people
  • Xianyang Hospital of Yan'an UniversityXianyang, ChinaContact: Fang Wang (principal investigator)Taking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT07353931EU 2025-523768-19-00
Record updated
4 November 2026
Original description
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.Read full original descriptionShow less

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Inclusion: Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening; Have a stable body weight (less than 5% body weight change) for 90 days prior to screening; Have tried at least once to lose weight through diet but were unsuccessful; Have osteoarthritis of the knee and at least one of the following conditions:; Be over 50 years old; Have morning knee stiffness that lasts about 30 minutes; Have a crackling or grinding sound or feeling in the knee.

Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have an active knee infection; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.

ClinicalTrials.gov NCT07353931 · EU CTIS 2025-523768-19-00